epirubicin has been researched along with Minimal Disease, Residual in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (23.08) | 18.2507 |
| 2000's | 11 (28.21) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Borgen, E; Børresen-Dale, AL; Engebraaten, O; Garred, Ø; Kristensen, V; Lien, T; Lingjaerde, OC; Lundgren, S; Naume, B; Schlichting, E; Silwal-Pandit, L; Skjerven, H; Tekpli, X; von der Lippe Gythfeldt, H; Wist, E | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, PC; Egle, D; Exner, R; Filipits, M; Fitzal, F; Frantal, S; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Muy-Kheng, TM; Petru, E; Petzer, AL; Pfeiler, G; Pichler, A; Rudas, M; Sevelda, P; Singer, CF; Stoeger, H; Tinchon, C; Wette, V | 1 |
| Chen, PY; Huang, CY; Lin, FW; Wang, CK; Wei, KC; Yang, HW | 1 |
| Adhi, MI; Kashif, S; Muhammad, K; Siyal, N | 1 |
| Anthoney, A; Germetaki, T; Kamposioras, K; Kordatou, Z; Mansoor, W; Nasralla, M; Owen-Holt, V; Papaxoinis, G; Stamatopoulou, S; Weaver, JMJ | 1 |
| du Bois, A; Harter, P; Hedderich, J; Heilmann, T; Hempel, AM; Hilpert, F; Pfisterer, J; Pujade-Lauraine, E; Saß, S | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Chen, Q; Fan, L; Jiang, J; Qi, X; Wang, S; Yang, X; Zhang, Y | 1 |
| Blaskowsky, LS; Enzinger, PZ; Hong, TS; Kwak, EL; Mamon, HJ; Mullen, JT; Ryan, DP; Schoenfeld, JD; Wo, JY | 1 |
| Duan, L; Fang, L; Long, X; Qu, H | 1 |
| Abrial, C; Bensussan, A; Curé, H; de Boissieu, P; Garbar, C; Kwiatkowski, F; Mombelli, S; Wang-Lopez, Q | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Kang, Y; Li, J; Ma, Y; Ren, W; Zang, L; Zhang, S | 1 |
| Bousamra, A; Brewster, AM; Buchholz, TA; Buzdar, AU; Gould, R; Hatzis, C; Hortobagyi, GN; Hunt, K; Liu, M; Moulder, S; Pusztai, L; Ramineni, M; Sinn, B; Symmans, WF; Valero, V; Walls, A; Wei, C; Yang, W; Yu, X; Zhang, Y | 1 |
| Buzdar, AU; Dawood, SS; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hatzis, C; Hortobagyi, GN; Kuerer, HM; Mejia, JA; Peintinger, F; Pusztai, L; Symmans, WF | 1 |
| Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C | 1 |
| Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G | 1 |
| Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Chang, HK; Chen, SC; Cheung, YC; Hsueh, S; Lin, YC; See, LC; Su, MY; Tsai, CS | 1 |
| Aguggini, S; Allevi, G; Alquati, P; Berruti, A; Bersiga, A; Bodini, M; Bottini, A; Brizzi, MP; Dogliotti, L; Fiorentino, C; Generali, D; Marini, U; Olivetti, L; Tampellini, M; Volpi, D | 1 |
| Arbion, F; Body, G; Brunereau, L; Chapiron, C; Denis, F; Desbiez-Bourcier, AV | 1 |
| Douek, M; Tobias, J | 1 |
| Alberti, S; Angelucci, D; Cianchetti, E; Ficorella, C; Iacobelli, S; Lattanzio, R; Marchetti, P; Natoli, C; Piantelli, M; Ricevuto, E; Tinari, N | 1 |
| Ah-See, ML; Beresford, MJ; Burcombe, R; Makris, A; Stott, D | 1 |
| Altundag, K; Buzdar, AU; Esteva, FJ; Hortobagyi, GN; Lin, F; Mejia, JA; Pusztai, L; Symmans, WF; Valero, V; Wang, J; Yan, K | 1 |
| Akesson, M; Andersson, H; Friberg, LG; Horvath, G; Johansson, O; Westberg, R | 1 |
| Eaton, M; Humeniuk, V; Kent, AL; Marshall, N | 1 |
| Abe, R; Hatakeyama, Y; Hoshino, M; Igarashi, W; Koyama, Y; Ohtake, T; Ono, T; Sato, N | 1 |
| Ichikawa, T; Kobayashi, Y; Matsuura, K; Miyata, M; Nagai, J; Shimanuki, K; Shinohara, K; Tanaka, O; Touru, M; Uraguchi, T | 1 |
| Algeri, R; Bellini, A; Boccardo, F; Brunetti, I; Bruzzone, M; Carnino, F; Catsafados, E; Chiara, S; Conte, PF; Foglia, G; Gadducci, A; Gallo, L; Iskra, L; Mammoliti, S; Parodi, G; Ragni, N; Rosso, R; Rubagotti, A; Rugiati, S | 1 |
| Athanassiou, A; Dimitriades, M; Kostopoulou, M; Mylonakis, A; Papadopoulou, M; Pectasides, D; Triantafillis, D; Varthalitis, J | 1 |
| Junkermann, H; von Fournier, D | 1 |
| Botti, G; Carriero, MV; Ciarmiello, A; D'Aiuto, G; Del Vecchio, S; Potena, MI; Salvatore, M; Silvestro, P; Thomas, R | 1 |
| Gnant, M; Jakesz, R; Locker, GJ; Schmidinger, M; Steger, GG; Taucher, S; Wenzel, C | 1 |
| Alessandroni, P; Antognoli, S; Bascioni, R; Bracci, R; Cellerino, R; Ciavattini, A; De Nictolis, M; Massacesi, C; Piga, A; Scartozzi, M | 1 |
| Baselli, EC; Greenberg, RE | 1 |
| Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R | 1 |
2 review(s) available for epirubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endoscopy, Digestive System; Epirubicin; Esophagectomy; Fluorouracil; Gastrectomy; Gastric Mucosa; Humans; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms | 2000 |
12 trial(s) available for epirubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Killer Cells, Natural; Lymphocytes, Tumor-Infiltrating; Macrophages; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Norway; Receptor, ErbB-2; Tumor Burden; Tumor Microenvironment | 2020 |
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Vaccines; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Tumor Burden | 2021 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Ultrasonography, Mammary | 2010 |
Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prospective Studies; Taxoids | 2004 |
How reliable is MRI for predicting extent of residual breast cancer with different primary medical therapies?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Taxoids | 2005 |
Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Databases, Factual; Disease Progression; Epirubicin; Female; Fluorouracil; Hemoglobins; Humans; Menopause; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Platelet Count; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Treatment Outcome | 2006 |
Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Laparotomy; Leukopenia; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Remission Induction; Reoperation; Survival Rate; Thrombocytopenia; Vomiting | 1995 |
[Efficacy of intrahepatic arterial chemotherapy to prevent recurrence of residual liver in metastatic liver cancer patients after hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Epirubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual | 1994 |
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Survival Rate; Treatment Outcome | 1996 |
Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Female; Humans; Lymph Node Excision; Mastectomy, Modified Radical; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Sestamibi | 1998 |
[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
25 other study(ies) available for epirubicin and Minimal Disease, Residual
| Article | Year |
|---|---|
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
Rapid
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Drug Therapy, Combination; Epirubicin; Gliosarcoma; Humans; Hydrogels; Infusion Pumps, Implantable; Magnetic Resonance Imaging; Mice; Neoplasm, Residual; Paclitaxel; Secondary Prevention; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured | 2017 |
Outcome of focal treatment to residual retinoblastoma after chemotherapy (Experience with Focal Treatment of Retinoblastoma).
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cryosurgery; Cyclophosphamide; Epirubicin; Female; Humans; Infant; Laser Coagulation; Male; Neoplasm, Residual; Neoplasms, Multiple Primary; Prospective Studies; Retinal Neoplasms; Retinoblastoma; Treatment Outcome; Vincristine | 2017 |
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Humans; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Perioperative Period; Propensity Score; Retrospective Studies; Survival Rate | 2019 |
Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Drug Administration Schedule; Epirubicin; Female; Humans; Medication Adherence; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Topotecan; Tumor Burden; Young Adult | 2019 |
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2013 |
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Epirubicin; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate | 2016 |
[Expression of ABCG2 and p-glycoprotein in residual breast cancer tissue after chemotherapy and their correlation with epithelial-mesenchymal transition].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cadherins; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; RNA, Messenger; Taxoids; Vimentin | 2014 |
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2015 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Elasticity Imaging Techniques; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; Taxoids; Trastuzumab; Treatment Outcome; Tumor Burden; Ultrasonography, Mammary | 2016 |
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Phenotype; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Rate; Time Factors; Trastuzumab; Tumor Burden | 2017 |
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Hormone-Dependent; Paclitaxel; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab | 2008 |
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; ROC Curve; Statistics, Nonparametric; Taxoids | 2010 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Prospective Studies; Remission Induction; Treatment Outcome | 2003 |
Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Drug Monitoring; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm, Residual; Palpation; Regression Analysis; Sensitivity and Specificity; Statistics, Nonparametric | 2004 |
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Proto-Oncogene Mas; Receptor, ErbB-2; Stereoisomerism | 2006 |
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; CD40 Antigens; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mastectomy; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; RNA, Messenger; Signal Transduction; Transcription, Genetic; Trastuzumab; Treatment Outcome; Up-Regulation | 2007 |
Locally advanced breast cancer: is surgery warranted following chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Mastectomy, Simple; Menopause; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Postoperative Care; Premenopause; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 1995 |
[A case of liver metastasis of leiomyosarcoma of residual stomach successfully treated by TAE and intra-hepato-arterial chemotherapy with infusion-a-port with administration of epirubicin].
Topics: Embolization, Therapeutic; Epirubicin; Gastrectomy; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neoplasm, Residual; Stomach Neoplasms; Treatment Outcome | 1994 |
CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Palliative Care; Prognosis; Prospective Studies; Sensitivity and Specificity; Stomach Neoplasms; Treatment Outcome | 1997 |
[Imaging methods for evaluating the response of breast carcinoma to preoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diagnostic Imaging; Epirubicin; Female; Humans; Neoplasm Staging; Neoplasm, Residual; Sensitivity and Specificity | 1997 |
Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Recurrence; Retrospective Studies; Survival Analysis | 2000 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Clinical Protocols; Clinical Trials, Phase II as Topic; Cystoscopy; Epirubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Neoplasm, Residual; Urinary Bladder Neoplasms | 2001 |